Bioenergetic dysfunction and inflammation in alzheimer's disease: A possible connection

Frontiers in Aging Neuroscience

Volumn 6, Issue OCT, 2014, Pages

  Wilkins, Heather M ^a,b   Carl, Steven M ^b   Greenlief, Alison ^b   Festoff, Barry W ^a,b,c   Swerdlow, Russell H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c pHLOGISTIX Neurodiagnostics   (United States)

Author keywords

Alzheimer's disease; Bioenergetics; DAMP; Inflammation; Mitochondria

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARDIOLIPIN; CRYOPYRIN; CYTOCHROME C; FORMYL METHIONINE LEUCINE PHENYLALANINE; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; AUTOPHAGY; BIOENERGY; CELL MOTILITY; CELL ORGANELLE; CELL PROLIFERATION; CHRONIC INFLAMMATION; ENCEPHALITIS; HUMAN; MITOCHONDRION; NONHUMAN; REVIEW; TIGHT JUNCTION;

EID: 84909590814     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00311     Document Type: Review

References (158)

1. Ishii T, Haga S. Immuno-electron microscopic localization of immunoglobulins in amyloid fibrils of senile plaques. Acta neuropathologica. 1976;36(3):243-9.
2. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994;44(2):227-32.
3. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti inflammatory drugs in Alzheimer's disease. Neurology. 1995;45(1):51-5.
4. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiology of Aging. 2000;21(3):383-421.
5. Akiyama H. Inflammatory response in Alzheimer's disease. The Tohoku journal of experimental medicine. 1994;174(3):295-303.
6. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer disease and associated disorders. 2000;14 Suppl 1:S47-53.
7. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain research Brain research reviews. 2005;48(1):16-42.
8. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiology of aging. 2000;21(3):383-421.
9. Versijpt JJ, Dumont F, Van Laere KJ, Decoo D, Santens P, Audenaert K, et al. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. European neurology. 2003;50(1):39-47.
10. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358(9280):461-7.
11. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. The New England journal of medicine. 2013;368(2):107-16.
12. Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science translational medicine. 2014;6(243):243ra86.
13. Jiang T, Yu JT, Zhu XC, Tan L. TREM2 in Alzheimer's disease. Molecular neurobiology. 2013;48(1):180-5.
14. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature genetics. 2011;43(5):429-35.
15. Hazrati LN, Van Cauwenberghe C, Brooks PL, Brouwers N, Ghani M, Sato C, et al. Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism. Neurobiology of aging. 2012;33(12):2949 e5-e12.
16. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature genetics. 2009;41(10):1094-9.
17. Harold D, Abraham R, Hollingworth P, Sims R, G errish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature genetics. 2009;41(10):1088-93.
18. Ivanov AI, Romanovsky AA. Putative dual role of ephrin-Eph receptor interactions in inflammation. IUBMB life. 2006;58(7):389-94.
19. Crocker PR, Varki A. Siglecs in the immune system. Immunology. 2001;103(2):137-45.
20. Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature. 1997;386(6622):296-9.
21. Marcus DL, Strafaci JA, Miller DC, Masia S, Thomas CG, Rosman J, et al. Quantitative neuronal c678 fos and c-jun expression in Alzheimer's disease. Neurobiology of aging. 1998;19(5):393-400.
22. McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Archives of neurology. 2001;58(11):1790-2.
23. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature genetics. 2013;45(12):1452-8.
24. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Archives of neurology. 2004;61(5):668-72.
25. Sundelof J, Kilander L, Helmersson J, Larsson A, Ronnemaa E, Degerman-Gunnarsson M, et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population689 based study. Journal of Alzheimer's disease: JAD. 2009;18(1):79-87.
26. Tan ZS, Beiser AS, Vasan RS, RoubenoffR, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007;68(22):1902-8.
27. Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A, et al. Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology. 2014.
28. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature reviews Neuroscience. 2007;8(1):57-69.
29. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-34.
30. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140(6):798-804.
31. Swerdlow RH. Bioenergetic medicine. Br J Pharmacol. 2014;171(8):1854-69.
32. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Annals of neurology. 1994;36(5):747-51.
33. Swerdlow RH. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxidants & redox signaling. 2012;16(12):1434-55.
34. Swerdlow RH. Brain aging, Alzheimer's disease, and mitochondria. Biochimica et biophysica acta. 2011;1812(12):1630-9.
35. Boveris A, Navarro A. Brain mitochondrial dysfunction in aging. IUBMB life. 2008;60(5):308-14.
36. Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. American journal of physiology Cell physiology. 2007;292(2):C670-86.
37. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature. 2004;429(6990):417-23.
38. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science. 2005;309(5733):481-4.
39. Ross JM, Stewart JB, Hagstrom E, Brene S, Mourier A, Coppotelli G, et al. Germline mitochondrial DNA mutations aggravate ageing and can impair brain development. Nature. 2013;501(7467):412-5.
40. Chetelat G, Landeau B, Salmon E, Yakushev I, Bahri MA, Mezenge F, et al. Relationships between brain metabolism decrease in normal aging and changes in structural and functional connectivity. NeuroImage. 2013;76:167-77.
41. De Santi S, de Leon MJ, Convit A, Tarshish C, Rusinek H, Tsui WH, et al. Age-related changes in brain: II. Positron emission tomography of frontal and temporal lobe glucose metabolism in normal subjects. The Psychiatric quarterly. 1995;66(4):357-70.
42. Marano CM, Workman CI, Kramer E, Hermann CR, Ma Y, Dhawan V, et al. Longitudinal studies of cerebral glucose metabolism in late-life depression and normal aging. International journal of geriatric psychiatry. 2013;28(4):417-23.
43. Navarro A, Boveris A. Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease. Frontiers in aging neuroscience. 2010;2.
44. Navarro A, Boveris A. Rat brain and liver mitochondria develop oxidative stress and lose enzymatic activities on aging. American journal of physiology Regulatory, integrative and comparative physiology. 2004;287(5):R1244-9.
45. Parker WD, Jr., Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology. 1990;40(8):1302-3.
46. Swerdlow RH, Kish SJ. Mitochondria in Alzheimer's disease. International review of neurobiology. 2002;53:341-85.
47. Bennett MC, Diamond DM, Stryker SL, Parks JK, Parker WD, Jr. Cytochrome oxidase inhibition: a novel animal model of Alzheimer's disease. Journal of geriatric psychiatry and neurology. 1992;5(2):93-101.
48. Ames BN, Shigenaga MK, Hagen TM. Mitochondrial decay in aging. Biochimica et biophysica acta. 1995;1271(1):165-70.
49. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(23):10771-8.
50. Hiona A, Sanz A, Kujoth GC, Pamplona R, Seo AY, Hofer T, et al. Mitochondrial DNA mutations induce mitochondrial dysfunction, apoptosis and sarcopenia in skeletal muscle of mitochondrial DNA mutator mice. PloS one. 2010;5(7):e11468.
51. Doherty TJ. Invited review: Aging and sarcopenia. Journal of applied physiology. 2003;95(4):1717-27.
52. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology. 1983;33(8):961-5.
53. Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain: a journal of neurology. 1981;104(Pt 4):753-78.
54. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. Journal of computer assisted tomography. 1983;7(4):590-8.
55. Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiology of Aging. 2002;23(3):371-6.
56. Maurer I, Zierz S, Möller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiology of Aging. 2000;21(3):455-62.
57. Manczak M, Park BS, Jung Y, Reddy PH. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular medicine. 2004;5(2):147-62.
58. Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochimica et biophysica acta. 2010;1802(1):122-34.
59. Onyango IG, Khan SM. Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Current Alzheimer research. 2006;3(4):339-49.
60. Kish SJ. Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase. Annals of the New York Academy of Sciences. 1997;826:218-28.
61. Honea RA, Vidoni ED, Swerdlow RH, Burns JM, Alzheimer's Disease Neuroimaging I. Maternal family history is associated with Alzheimer's disease biomarkers. Journal of Alzheimer's disease: JAD. 2012;31(3):659-68.
62. Edland SD, Silverman JM, Peskind ER, Tsuang D, Wijsman E, Morris JC. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology. 1996;47(1):254-6.
63. Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia E, et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(48):19067-72.
64. Swerdlow RH. Mitochondrial DNA--related mitochondrial dysfunction in neurodegenerative diseases. Archives of pathology & laboratory medicine. 2002;126(3):271-80.
65. Wilkins HM, Carl SM, Swerdlow RH. Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies. Redox Biology. 2014;2:619-31.
66. Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD, et al. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1997;17(12):4612-22.
67. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP, Jr., et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 1997;49(4):918-25.
68. Silva DF, Selfridge JE, Lu J, E L, Cardoso SM, Swerdlow RH. Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. Advances in pharmacology. 2012;64:83-126.
69. Silva DF, Santana I, Esteves AR, Baldeiras I, Arduino DM, Oliveira CR, et al. Prodromal metabolic phenotype in MCI cybrids: implications for Alzheimer's disease. Current Alzheimer research. 2013;10(2):180-90.
70. Ghosh SS, Swerdlow RH, Miller SW, Sheeman B, Parker WD, Jr., Davis RE. Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann N Y Acad Sci. 1999;893:176-91.
71. Onyango IG, Bennett JP, Jr., Tuttle JB. Endogenous oxidative stress in sporadic Alzheimer's disease neuronal cybrids reduces viability by increasing apoptosis through pro-death signaling pathways and is mimicked by oxidant exposure of control cybrids. Neurobiol Dis. 2005;19(1-2):312-22.
72. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Medical hypotheses. 2004;63(1):8-20.
73. Babior BM. NADPH oxidase. Current opinion in immunology. 2004;16(1):42-7.
74. Di Filippo M, Chiasserini D, Tozzi A, Picconi B, Calabresi P. Mitochondria and the link between neuroinflammation and neurodegeneration. Journal of Alzheimer's disease: JAD. 2010;20 Suppl 2:S369-79.
75. Fukui H, Moraes CT. The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis? Trends in neurosciences. 2008;31(5):251-6.
76. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120(4):483-95.
77. Brown GC. Nitric oxide inhibition of cytochrome oxidase and mitochondrial respiration: implications for inflammatory, neurodegenerative and ischaemic pathologies. Molecular and cellular biochemistry. 1997;174(1-2):189-92.
78. Shaikh SB, Nicholson LF. Effects of chronic low dose rotenone treatment on human microglial cells. Molecular neurodegeneration. 2009;4:55.
79. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience letters. 2003;341(2):87-90.
80. Gao HM, Liu B, Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2003;23(15):6181-7.
81. Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2003;17(13):1954-6.
82. Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson's disease. Progress in neurobiology. 2009;89(3):277-87.
83. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2008;23(4):474-83.
84. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221-5.
85. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nature immunology. 2011;12(3):222-30.
86. Cristina Kenney M, Chwa M, Atilano SR, Falatoonzadeh P, Ramirez C, Malik D, et al. Inherited mitochondrial DNA variants can affect complement, inflammation and apoptosis pathways: insights into mitochondrial-nuclear interactions. Human molecular genetics. 2014;23(13):3537-51.
87. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104-7.
88. Collins LV, Hajizadeh S, Holme E, Jonsson IM, Tarkowski A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. Journal of leukocyte biology. 2004;75(6):995-1000.
89. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nature clinical practice Rheumatology. 2007;3(7):382-90.
90. Pullerits R, Bokarewa M, Jonsson IM, Verdrengh M, Tarkowski A. Extracellular cytochrome c, a mitochondrial apoptosis-related protein, induces arthritis. Rheumatology. 2005;44(1):32-9.
91. van Golen RF, Reiniers MJ, Olthof PB, van Gulik TM, Heger M. Sterile inflammation in hepatic ischemia/reperfusion injury: present concepts and potential therapeutics. Journal of gastroenterology and hepatology. 2013;28(3):394-400.
92. Walko TD, 3rd, Bola RA, Hong JD, Au AK, Bell MJ, Kochanek PM, et al. Cerebrospinal fluid mitochondrial DNA: a novel DAMP in pediatric traumatic brain injury. Shock. 2014;41(6):499-503.
93. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2006;20(14):2565-6.
94. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38(2):209-23.
95. Julian MW, Shao G, Bao S, Knoell DL, Papenfuss TL, VanGundy ZC, et al. Mitochondrial transcription factor A serves as a danger signal by augmenting plasmacytoid dendritic cell responses to DNA. Journal of immunology. 2012;189(1):433-43.
96. Crouser ED, Shao G, Julian MW, Macre JE, Shadel GS, Tridandapani S, et al. Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors. Critical care medicine. 2009;37(6):2000-9.
97. Julian MW, Shao G, Vangundy ZC, Papenfuss TL, Crouser ED. Mitochondrial transcription factor A, an endogenous danger signal, promotes TNFalpha release via RAGE- and TLR9-responsive plasmacytoid dendritic cells. PloS one. 2013;8(8):e72354.
98. Nakahira K, Kyung SY, Rogers AJ, Gazourian L, Youn S, Massaro AF, et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS medicine. 2013;10(12):e1001577; discussion e.
99. Mathew A, Lindsley TA, Sheridan A, Bhoiwala DL, Hushmendy SF, Yager EJ, et al. Degraded mitochondrial DNA is a newly identified subtype of the damage associated molecular pattern (DAMP) family and possible trigger of neurodegeneration. Journal of Alzheimer's disease: JAD. 2012;30(3):617-27.
100. Zhang JZ, Liu Z, Liu J, Ren JX, Sun TS. Mitochondrial DNA induces inflammation and increases TLR9/NF-kappaB expression in lung tissue. International journal of molecular medicine. 2014;33(4):817-24.
101. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature. 2012;485(7397):251-5.
102. Little JP, Simtchouk S, Schindler SM, Villanueva EB, Gill NE, Walker DG, et al. Mitochondrial transcription factor A (Tfam) is a pro-inflammatory extracellular signaling molecule recognized by brain microglia. Molecular and cellular neurosciences. 2014;60:88-96.
103. Ishii Y, Nagasawa K, Mayumi T, Niho Y. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Annals of the rheumatic diseases. 1990;49(6):387-90.
104. Wan M, Hua X, Su J, Thiagarajan D, Frostegard AG, Haeggstrom JZ, et al. Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5. Atherosclerosis. 2014;235(2):592-8.
105. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends in immunology. 2011;32(4):157-64.
106. Mamula MJ, Jemmerson R, Hardin JA. The specificity of human anti-cytochrome c autoantibodies that arise in autoimmune disease. Journal of immunology. 1990;144(5):1835-40.
107. Kurashima Y, Amiya T, Nochi T, Fujisawa K, Haraguchi T, Iba H, et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nature communications. 2012;3:1034.
108. Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P. Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell death & disease. 2014;5:e1102.
109. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, et al. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. American journal of respiratory and critical care medicine. 2010;182(6):774-83.
110. Gourine AV, Dale N, Llaudet E, Poputnikov DM, Spyer KM, Gourine VN. Release of ATP in the central nervous system during systemic inflammation: real-time measurement in the hypothalamus of conscious rabbits. The Journal of physiology. 2007;585(Pt 1):305-16.
111. Hide I, Tanaka M, Inoue A, Nakajima K, Kohsaka S, Inoue K, et al. Extracellular ATP triggers tumor necrosis factor-alpha release from rat microglia. Journal of neurochemistry. 2000;75(3):965-72.
112. Kucher BM, Neary JT. Bi-functional effects of ATP/P2 receptor activation on tumor necrosis factor-alpha release in lipopolysaccharide-stimulated astrocytes. Journal of neurochemistry. 2005;92(3):525-35.
113. Choi HB, Ryu JK, Kim SU, McLarnon JG. Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2007;27(18):4957-68.
114. Suzuki T, Hide I, Ido K, Kohsaka S, Inoue K, Nakata Y. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2004;24(1):1-7.
115. Pan ZK, Chen LY, Cochrane CG, Zuraw BL. fMet-Leu-Phe Stimulates Proinflammatory Cytokine Gene Expression in Human Peripheral Blood Monocytes: The Role of Phosphatidylinositol 3-Kinase. The Journal of Immunology. 2000;164(1):404-11.
116. Sodhi A, Biswas SK. fMLP-induced in vitro nitric oxide production and its regulation in murine peritoneal macrophages. Journal of leukocyte biology. 2002;71(2):262-70.
117. Raoof M, Zhang Q, Itagaki K, Hauser CJ. Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. The Journal of trauma. 2010;68(6):1328-32; discussion 32-4.
118. Gao X, Hu X, Qian L, Yang S, Zhang W, Zhang D, et al. Formyl-methionyl-leucyl-phenylalanine919 induced dopaminergic neurotoxicity via microglial activation: a mediator between peripheral infection and neurodegeneration? Environmental health perspectives. 2008;116(5):593-8.
119. Stumbo AC, Cortez E, Rodrigues CA, Henriques M, Porto LC, Barbosa HS, et al. Mitochondrial localization of non-histone protein HMGB1 during human endothelial cell-Toxoplasma gondii infection. Cell biology international. 2008;32(2):235-8.
120. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. The Journal of cell biology. 2010;190(5):881-92.
121. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annual review of immunology. 2011;29:139-62.
122. Mazarati A, Maroso M, Iori V, Vezzani A, Carli M. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. Experimental neurology. 2011;232(2):143-8.
123. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191-5.
124. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation934 promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101(7):2652-60.
125. Davis CH, Kim KY, Bushong EA, Mills EA, Boassa D, Shih T, et al. Transcellular degradation of axonal mitochondria. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(26):9633-8.
126. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. Journal of neuroinflammation. 2008;5:7.
127. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nature reviews Immunology. 2013;13(6):397-411.
128. Vazquez-Higuera JL, Rodriguez-Rodriguez E, Sanchez-Juan P, Mateo I, Pozueta A, Martinez-Garcia A, et al. Caspase-1 genetic variation is not associated with Alzheimer's disease risk. BMC medical genetics. 2010;11:32.
129. Griffin WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE. The pervasiveness of interleukin-1 in alzheimer pathogenesis: a role for specific polymorphisms in disease risk. Experimental gerontology. 2000;35(4):481-7.
130. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience letters. 1995;202(1-2):17-20.
131. Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods and findings in experimental and clinical pharmacology. 1991;13(7):455-8.
132. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? Journal of neuroimmunology. 2000;103(1):97-102.
133. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(19):7611-5.
134. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674-8.
135. de Rivero Vaccari JP, Brand FJ, 3rd, Sedaghat C, Mash DC, Dietrich WD, Keane RW. RIG-1 receptor expression in the pathology of Alzheimer's disease. Journal of neuroinflammation. 2014;11:67.
136. Wang LZ, Yu JT, Miao D, Wu ZC, Zong Y, Wen CQ, et al. Genetic association of TLR4/11367 polymorphism with late-onset Alzheimer's disease in a Han Chinese population. Brain research. 2011;1381:202-7.
137. Wang YL, Tan MS, Yu JT, Zhang W, Hu N, Wang HF, et al. Toll-like receptor 9 promoter polymorphism is associated with decreased risk of Alzheimer's disease in Han Chinese. Journal of neuroinflammation. 2013;10(1):101.
138. Balistreri CR, Grimaldi MP, Chiappelli M, Licastro F, Castiglia L, Listi F, et al. Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease. Current pharmaceutical design. 2008;14(26):2672-7.
139. Yu JT, Mou SM, Wang LZ, Mao CX, Tan L. Toll-like receptor 2-196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer's disease. Journal of neuroinflammation. 2011;8:136.
140. Yu JT, Sun YP, Ou JR, Cui WZ, Zhang W, Tan L. No association of toll-like receptor 2 polymorphisms with Alzheimer's disease in Han Chinese. Neurobiology of aging. 2011;32(10):1924 e1-3.
141. Zhang W, Wang LZ, Yu JT, Chi ZF, Tan L. Increased expressions of TLR2 and TLR4 on peripheral blood mononuclear cells from patients with Alzheimer's disease. Journal of the neurological sciences. 2012;315(1-2):67-71.
142. Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiology of aging. 2009;30(5):759-68.
143. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain: a journal of neurology. 2005;128(Pt 8):1778-89.
144. Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2007;20(6):947-56.
145. Cojocaru IM, Cojocaru M, Miu G, Sapira V. Study of interleukin-6 production in Alzheimer's disease. Romanian journal of internal medicine = Revue roumaine de medecine interne. 2011;49(1):55-8.
146. Singh VK, Guthikonda P. Circulating cytokines in Alzheimer's disease. Journal of psychiatric research. 1997;31(6):657-60.
147. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biological psychiatry. 2010;68(10):930-41.
148. Alsadany MA, Shehata HH, Mohamad MI, Mahfouz RG. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease. American journal of Alzheimer's disease and other dementias. 2013;28(1):54-61.
149. Lim JE, Kou J, Song M, Pattanayak A, Jin J, Lalonde R, et al. MyD88 deficiency ameliorates beta1001 amyloidosis in an animal model of Alzheimer's disease. The American journal of pathology. 2011;179(3):1095-103.
150. Verdier Y, Zarandi M, Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. Journal of peptide science: an official publication of the European Peptide Society. 2004;10(5):229-48.
151. Xie J, Mendez JD, Mendez-Valenzuela V, Aguilar-Hernandez MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cellular signalling. 2013;25(11):2185-97.
152. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Experimental neurology. 2001;171(1):29-45.
153. Podlesniy P, Figueiro-Silva J, Llado A, Antonell A, Sanchez-Valle R, Alcolea D, et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of neurology. 2013;74(5):655-68.
154. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of general psychiatry. 2012;69(1):98-106.
155. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Archives of neurology. 2000;57(1):100-5.
156. Wallin AK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dementia and geriatric cognitive disorders. 2006;21(3):131-8.
157. Papaliagkas VT, Anogianakis G, Tsolaki MN, Koliakos G, Kimiskidis VK. Prediction of conversion from mild cognitive impairment to Alzheimer's disease by CSF cytochrome c levels and N200 latency. Current Alzheimer research. 2009;6(3):279-84.
158. Piccini A, Carta S, Tassi S, Lasiglie D, Fossati G, Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(23):8067-72.